BTK and B-cell chronic lymphocytic leukemia: Since about 2015, novel inhibitors of kinases in the B-cell receptor signalling pathway, PI3Kδ and BTK; BCL2 antagonist, venetoclax; and further CD-20 inhibitors have transformed the recent management of CLL patients [1,6,7].